CIDP
Clinical trials for CIDP explained in plain language.
Never miss a new study
Get alerted when new CIDP trials appear
Sign up with your email to follow new studies for CIDP, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Tracking a new Treatment's Real-World impact on debilitating nerve disease
Disease control Recruiting nowThis study aims to understand how well a medication called efgartigimod works for people with CIDP in real-world settings, outside of a controlled clinical trial. It will follow 200 adults with CIDP for up to two years after they start this treatment, tracking their symptoms, dai…
Matched conditions: CIDP
Sponsor: argenx • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New hope for nerve disorder patients through special access program
Disease control AVAILABLEThis program provides early access to an investigational treatment called efgartigimod PH20 SC for adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disorder. It's designed for patients who can't join regular clinical trials and haven't found relief fr…
Matched conditions: CIDP
Sponsor: argenx • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New drug trial offers hope for nerve disease patients
Disease control Recruiting nowThis study aims to see if a new intravenous drug called empasiprubart works as well as or better than the current standard treatment (IVIg) for adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disorder that causes weakness. For the first 6 months, par…
Matched conditions: CIDP
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
New hope for nerve disease: major trial tests potential CIDP treatment
Disease control Recruiting nowThis study is testing whether an investigational medicine called empasiprubart is safe and can help adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), a nerve disorder that causes weakness and disability. For the first 6 months, some participants will receive t…
Matched conditions: CIDP
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
Could your weight change your medication dose?
Knowledge-focused Recruiting nowThis study aims to understand how a person's body composition (like muscle and fat) affects the levels of immunoglobulin medication in their blood. It will enroll 20 adults with a nerve disorder called CIDP who receive this medication. Researchers will measure drug levels after p…
Matched conditions: CIDP
Phase: PHASE1 • Sponsor: Rutgers, The State University of New Jersey • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:33 UTC